Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.

Publication Type:

Journal Article


Clinical breast cancer, Volume 15, Issue 5, p.e277-85 (2015)


Research Trials Office Core Facility - Biostatistics Service


Commonly used adjuvant systemic therapies harbor high rates of severe short-term and long-term side effects but are often justified to patients because of curative intent in early-stage breast cancer. One of the oldest and least toxic adjuvant regimens, CMF (oral cyclophosphamide given with intravenous methotrexate and 5-fluourouracil), has been largely abandoned because of the perception that it underperforms for survival outcomes compared with modern regimens containing anthracycline and/or taxanes.